Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07033481 · ClinicalTrials.gov registry record · Phase 2
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
A Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA), sponsored by EIP Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT07033481 is a Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA) that is actively recruiting participants, run by EIP Pharma. The registered enrollment target is 20 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07033481, a Phase 2 study of Nonfluent Variant Primary Progressive Aphasia (nfvPPA), is actively recruiting participants, sponsored by EIP Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Neflamapimod
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
Ohio
- The Ohio State University - Columbus
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-08 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07033481
The ClinicalTrials.gov registry entry for NCT07033481 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EIP Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nonfluent Variant Primary Progressive Aphasia (nfvPPA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07033481 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07033481 about?
NCT07033481 is a clinical study titled "Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia". The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
What is the current status of trial NCT07033481?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-08. Estimated completion is 2026-10.
What conditions does trial NCT07033481 study?
This clinical trial studies the following conditions: Nonfluent Variant Primary Progressive Aphasia (nfvPPA).
What interventions are being tested in trial NCT07033481?
The interventions under investigation include: Placebo (DRUG), Neflamapimod (DRUG).
Who is sponsoring clinical trial NCT07033481?
This trial is sponsored by EIP Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07033481 being conducted?
This trial has 3 study locations across Minnesota, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.